@inproceedings{01HSTHT16MJYKQXB0S6NWWZ4HW,
  abstract     = {{Background
Circulating tumor cells (CTCs) are cancer cells that enter the circulatory system and form distant metastases. CTCs are shown to be strongly associated with poor survival and therapy failure and thus present an opportunity to monitor disease. Parsortix is a size-based microfluidic system for CTC enrichment, which was recently FDA approved for CTC detection in metastatic breast cancer patients. The suitability of the Parsortix instrument for the isolation of pancreatic CTCs has not been previously investigated. The aim of our study is to determine the recovery rates of the Parsortix instrument for different pancreatic cancer cell subtypes. 
Methods
Three pancreatic cancer cell lines were used in this study: CAPAN-1, PANC-1 and MIA-PaCa-2. An in-depth proteome analysis was performed using data-independent acquisition (DIA)-mass spectrometry (MS) to identify differentially expressed proteins. In addition, we stained each cell line with a different CellTracker dye and spiked them into blood from healthy donors. We processed the samples using the Parsortix system and determined the recovery rates by quantifying the number of cancer cells in the separation cassette using fluorescence microscopy.
Results
MS analysis identified a total of 6590 proteins in all cell lines. By evaluating levels of currently used protein markers for Epithelial Mesenchymal Transition (EMT) such as EpCAM, cytokeratin and vimentin, we were able to characterize CAPAN-1, MIA-PaCa-2, and PANC-1 as epithelial, mesenchymal and intermediate cells respectively.
The three cell lines were fluorescently labeled for marker-independent detection in the Parsortix. Our preliminary results suggest that MIA-PaCa-2 (mesenchymal cells) may have a lower recovery rate (36%) with the Parsortix system compared to CAPAN-1 (epithelial cells) (41%). The overall recovery rates were also lower than expected compared to current literature. Additional experiments are ongoing to confirm these findings. 
Conclusions
Overall, our study highlights the importance of evaluating the recovery rates of different CTC subtypes to develop more effective methods for capturing the heterogeneity of CTCs in liquid biopsies. Further experiments are needed to confirm the Parsortix system's ability to enrich mesenchymal CTCs as effectively as epithelial CTCs in patients with pancreatic cancer.}},
  articleno    = {{PP034}},
  author       = {{Vandenbussche, Nele and Parton, Bram and Merckaert, Tijs and Fieuws, Charlotte and Abreu de Carvalho, Luis and Berrevoet, Frederik and Gevaert, Kris and Claes, Kathleen}},
  booktitle    = {{6th ACTC Advances in Circulating Tumor Cells 'Liquid Biopsy and Precision Oncology : Where do we stand now?' Book of Abstracts}},
  language     = {{eng}},
  location     = {{Skiathos, Greece}},
  title        = {{Assessing recovery rates of mesenchymal and epithelial pancreatic tumor cells using the Parsortix system}},
  url          = {{https://www.erasmus.gr/UsersFiles/microsite1261/Documents/ACTC2023_BOOKOFABSTRACTS_Final_updated.pdf}},
  year         = {{2023}},
}